{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:44:08Z","timestamp":1778928248802,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201300015I"],"award-info":[{"award-number":["HHSN272201300015I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with cystic fibrosis (CF) experience recurrent bacterial pulmonary exacerbations. Management of these infections is increasingly challenging due to decreased antimicrobial susceptibility to \u03b2-lactam antibiotics. The pharmacokinetics (PK) of these agents are inadequately characterized in patients with CF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study enrolled 155 pediatric and adult participants with CF who were receiving the following \u03b2-lactam antibiotics: cefepime (n = 82), meropenem (n = 42), or piperacillin-tazobactam (n = 31). Opportunistic blood samples were obtained during hospitalization. Population PK analysis was conducted via nonlinear mixed effects modeling. Clinical and demographic characteristics were evaluated as potential covariates. Monte Carlo simulations were performed to evaluate the probability of target attainment (PTA) for different dosing regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Estimated creatinine clearance and total or lean body weight affected the PK of cefepime and meropenem. No covariates were identified for piperacillin and tazobactam. In the cefepime group, a 3-hour infusion achieved a higher PTA than a 0.5-hour infusion for all participants. Estimated breakpoints\u2014the respective minimum inhibitory concentration up to which \u226590% of patients are predicted to reach a PK\/pharmacodynamic target\u2014were 2- to 4-fold higher in pediatric participants receiving a 3- vs 0.5-hour infusion. In the meropenem group, increased creatinine clearance led to reduced PTA. In the piperacillin-tazobactam group, total daily dose and mode of administration were principal drivers of PTA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Standard dosing regimens fail to achieve specific minimum inhibitory concentration targets in patients with CF. Therefore, clinicians should incorporate local antibiograms and PK models to determine optimal dosing. Further PK optimization to account for interindividual differences could be achieved by real-time \u03b2-lactam therapeutic drug monitoring.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae451","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T19:23:29Z","timestamp":1727292209000},"page":"e364-e374","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-2222","authenticated-orcid":false,"given":"Stephanie L","family":"Rolsma","sequence":"first","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"},{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5495-1237","authenticated-orcid":false,"given":"Andrew","family":"Sokolow","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8660-1023","authenticated-orcid":false,"given":"Pratish C","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Sokolow","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-9127","authenticated-orcid":false,"given":"Natalia","family":"Jimenez-Truque","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"},{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3960-3998","authenticated-orcid":false,"given":"William H","family":"Fissell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Ryan","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5715-1534","authenticated-orcid":false,"given":"Carl M","family":"Kirkpatrick","sequence":"additional","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences, Monash University , Parkville ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-8590","authenticated-orcid":false,"given":"Roger L","family":"Nation","sequence":"additional","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences, Monash University , Parkville ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9621-8439","authenticated-orcid":false,"given":"Kenan","family":"Gu","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Teresi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Fishbane","sequence":"additional","affiliation":[{"name":"The Emmes Company LLC , Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Kontos","sequence":"additional","affiliation":[{"name":"The Emmes Company LLC , Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-7663","authenticated-orcid":false,"given":"Guohua","family":"An","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4826-1790","authenticated-orcid":false,"given":"Patricia","family":"Winokur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-4743","authenticated-orcid":false,"given":"Cornelia B","family":"Landersdorfer","sequence":"additional","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences, Monash University , Parkville ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-9053","authenticated-orcid":false,"given":"C Buddy","family":"Creech","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"},{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"2025022016350719800_jiae451-B1","author":"Anbar"},{"key":"2025022016350719800_jiae451-B2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: an overview","volume":"65","author":"Turcios","year":"2020","journal-title":"Respir Care"},{"key":"2025022016350719800_jiae451-B3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"key":"2025022016350719800_jiae451-B4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ppul.10100","article-title":"Predictors of deterioration of lung function in cystic fibrosis","volume":"33","author":"Schaedel","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"2025022016350719800_jiae451-B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02914541","article-title":"Pharmacokinetics of drugs in cystic fibrosis","volume":"9","author":"Spino","year":"1991","journal-title":"Clin Rev Allergy"},{"key":"2025022016350719800_jiae451-B6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40262-018-0678-x","article-title":"Four decades of beta-lactam antibiotic pharmacokinetics in cystic fibrosis","volume":"58","author":"Bulitta","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2025022016350719800_jiae451-B7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40262-020-00970-3","article-title":"Antibiotics in adult cystic fibrosis patients: a review of population pharmacokinetic analyses","volume":"60","author":"El Hassani","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2025022016350719800_jiae451-B8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-020-00981-0","article-title":"Pharmacokinetic and pharmacodynamic optimization of antibiotic therapy in cystic fibrosis patients: current evidences, gaps in knowledge and future directions","volume":"60","author":"Magr\u00e9ault","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2025022016350719800_jiae451-B9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cca.2018.08.008","article-title":"Beta-lactam carryover in arterial and central venous catheters is negligible","volume":"486","author":"Marsh","year":"2018","journal-title":"Clin Chim Acta"},{"key":"2025022016350719800_jiae451-B10","doi-asserted-by":"crossref","first-page":"e00859-18","DOI":"10.1128\/AAC.00859-18","article-title":"Quantification of cefepime, meropenem, piperacillin, and tazobactam in human plasma using a sensitive and robust liquid chromatography-tandem mass spectrometry method, part 1: assay development and validation","volume":"62","author":"D\u2019Cunha","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025022016350719800_jiae451-B11","doi-asserted-by":"crossref","first-page":"e00861-18","DOI":"10.1128\/AAC.00861-18","article-title":"Quantification of cefepime, meropenem, piperacillin, and tazobactam in human plasma using a sensitive and robust liquid chromatography-tandem mass spectrometry method, part 2: stability evaluation","volume":"62","author":"D\u2019Cunha","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025022016350719800_jiae451-B12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2025022016350719800_jiae451-B13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2165\/00003088-199325020-00002","article-title":"Cefepime clinical pharmacokinetics","volume":"25","author":"Okamoto","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"2025022016350719800_jiae451-B14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.27.2.207","article-title":"Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics","volume":"27","author":"Kessler","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"2025022016350719800_jiae451-B15","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1093\/clinids\/24.Supplement_2.S266","article-title":"The pharmacology of meropenem, a new carbapenem antibiotic","volume":"24","author":"Craig","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"Suppl A","key":"2025022016350719800_jiae451-B16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/31.suppl_A.39","article-title":"The chemistry, pharmacokinetics and tissue distribution of piperacillin\/tazobactam","volume":"31","author":"Sorgel","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"2025022016350719800_jiae451-B17","doi-asserted-by":"crossref","first-page":"e02306-17","DOI":"10.1128\/AAC.02306-17","article-title":"Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered?","volume":"62","author":"Andersen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025022016350719800_jiae451-B18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijantimicag.2019.06.016","article-title":"Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic\/pharmacodynamic analysis","volume":"54","author":"Ehmann","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025022016350719800_jiae451-B19","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025022016350719800_jiae451-B20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ppul.25817","article-title":"Evaluation of the safety of cefepime prolonged infusions in pediatric patients with cystic fibrosis","volume":"57","author":"Imburgia","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2025022016350719800_jiae451-B21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ejhpharm-2022-003535","article-title":"Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection","volume":"31","author":"Murinova","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"2025022016350719800_jiae451-B22","doi-asserted-by":"crossref","first-page":"e0131222","DOI":"10.1128\/aac.01312-22","article-title":"Evaluation of empirical dosing regimens for meropenem in intensive care unit patients using population pharmacokinetic modeling and target attainment analysis","volume":"67","author":"An","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025022016350719800_jiae451-B23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/jac\/dkv289","article-title":"Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis","volume":"71","author":"Pettit","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025022016350719800_jiae451-B24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkl053","article-title":"Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis","volume":"57","author":"Han","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2025022016350719800_jiae451-B25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2025022016350719800_jiae451-B26","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.ejps.2017.05.021","article-title":"Combined proportional and additive residual error models in population pharmacokinetic modelling","volume":"109","author":"Proost","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"2025022016350719800_jiae451-B27","author":"Gastonguay"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae451\/59619398\/jiae451.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/2\/e364\/59619398\/jiae451.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/2\/e364\/59619398\/jiae451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:36:29Z","timestamp":1740069389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/2\/e364\/7793196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,30]]},"published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae451","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,9,30]]}}}